autologous islet transplantation
Recently Published Documents


TOTAL DOCUMENTS

58
(FIVE YEARS 7)

H-INDEX

13
(FIVE YEARS 1)

2022 ◽  
Vol 23 ◽  
Author(s):  
Rachel P. Tindall ◽  
Suzanne Bertera ◽  
Tadahiro Uemura ◽  
Molly Vincent ◽  
Michael F. Knoll ◽  
...  

2021 ◽  
Vol 10 (12) ◽  
pp. 2723
Author(s):  
Beata Jabłońska ◽  
Sławomir Mrowiec

Total pancreatectomy is a major complex surgical procedure involving removal of the whole pancreatic parenchyma and duodenum. It leads to lifelong pancreatic exocrine and endocrine insufficiency. The control of surgery-induced diabetes (type 3) requires insulin therapy. Total pancreatectomy with autologous islet transplantation (TPAIT) is performed in order to prevent postoperative diabetes and its serious complications. It is very important whether it is safe and beneficial for patients in terms of postoperative morbidity and mortality, and long-term results including quality of life. Small duct painful chronic pancreatitis (CP) is a primary indication for TPAIT, but currently the indications for this procedure have been extended. They also include hereditary/genetic pancreatitis (HGP), as well as less frequent indications such as benign/borderline pancreatic tumors (intraductal papillary neoplasms, neuroendocrine neoplasms) and “high-risk pancreatic stump”. The use of TPAIT in malignant pancreatic and peripancreatic neoplasms has been reported in the worldwide literature but currently is not a standard but rather a controversial management in these patients. In this review, history, technique, indications, and contraindications, as well as short-term and long-term results of TPAIT, including pediatric patients, are described.


2021 ◽  
Author(s):  
Xiaofei Zhang ◽  
Zhuo Ma ◽  
Eli Song ◽  
Tao Xu

AbstractStudies on diabetes have long been hampered by a lack of authentic disease models that, ideally, should be unlimited and able to recapitulate the abnormalities involved in the development, structure, and function of human pancreatic islets under pathological conditions. Stem cell-based islet organoids faithfully recapitulate islet development in vitro and provide large amounts of three-dimensional functional islet biomimetic materials with a morphological structure and cellular composition similar to those of native islets. Thus, islet organoids hold great promise for modeling islet development and function, deciphering the mechanisms underlying the onset of diabetes, providing an in vitro human organ model for infection of viruses such as SARS-CoV-2, and contributing to drug screening and autologous islet transplantation. However, the currently established islet organoids are generally immature compared with native islets, and further efforts should be made to improve the heterogeneity and functionality of islet organoids, making it an authentic and informative disease model for diabetes. Here, we review the advances and challenges in the generation of islet organoids, focusing on human pluripotent stem cell-derived islet organoids, and the potential applications of islet organoids as disease models and regenerative therapies for diabetes.


2021 ◽  
Vol 30 ◽  
pp. 096368972110574
Author(s):  
Ruth E. McDowell ◽  
Khawla F. Ali ◽  
Saloni Lad ◽  
Vicente T. San Martin ◽  
Rita Bottino ◽  
...  

The inflammatory response is an obstacle to success in both allogeneic and autologous islet transplantation. In autologous islet transplantation (AIT), however, the recipient is also the donor, permitting pretreatment of donor/recipient for a controlled duration prior to transplantation. We sought to exploit this feature of (AIT) by pretreating donor/recipients with chronic pancreatitis undergoing total pancreatectomy and autologous islet transplantation (TPAIT) to test the hypothesis that peri-transplant treatment with the FDA-approved anti-inflammatory hydroxychloroquine (HCQ) improves graft function. In this randomized placebo-controlled pilot clinical study, patients ( n = 6) were treated with oral HCQ for 30 days prior to and 90 days after TPAIT. In vivo islet function was assessed via Mixed Meal Tolerance Testing before HCQ treatment, 6- and 12-months after surgery. In vitro islet bioenergetics were assessed at the time of transplantation via extracellular flux analysis of islet preparation samples from the clinical trial cohort and six additional patients ( n = 12). Our study shows that HCQ did not alter clinical endpoints, but HCQ-treated patients showed greater spare respiratory capacity (SRC) compared to samples from control patients ( P=0.028). Glycolytic metabolism of islet preparations directly correlated with stimulated C-peptide secretion both before and after TPAIT ( P=0.01, R 2=0.489 and P=0.03, R 2=0.674, respectively), and predicted in vivo islet function better than mitochondrial metabolism of islet preps or islet equivalents infused. Overnight culture of islet preparations altered bioenergetic function, significantly decreasing SRC and maximal respiration ( P<0.001). In conclusion, while HCQ did not alter clinical outcomes, it was associated with significantly increased SRC in islet preparations. Bioenergetic analyses of islet preparations suggests that culture should be avoided and that glycolysis may be a more sensitive indicator of in vivo islet function than current metrics, including islet oxygen consumption and islet equivalents infused.


Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 219-OR
Author(s):  
RUTH MCDOWELL ◽  
KHAWLA F. ALI ◽  
VICENTE T. SAN MARTIN ◽  
RITA BOTTINO ◽  
JOHN P. KIRWAN ◽  
...  

Pancreas ◽  
2019 ◽  
Vol 48 (5) ◽  
pp. 656-661 ◽  
Author(s):  
Khawla F. Ali ◽  
Vicente T. San Martin ◽  
R. Matthew Walsh ◽  
Rita Bottino ◽  
Tyler Stevens ◽  
...  

2018 ◽  
Vol 2 (3) ◽  
pp. 1-1
Author(s):  
Khawla F. Ali ◽  
◽  
Vicente T. San Martin ◽  
Tyler Stevens ◽  
R. Matthew Walsh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document